These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 20627594)

  • 1. Inhibition of prolyl oligopeptidase with a synthetic unnatural dipeptide.
    Racys DT; Rea D; Fülöp V; Wills M
    Bioorg Med Chem; 2010 Jul; 18(13):4775-82. PubMed ID: 20627594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).
    Haffner CD; Diaz CJ; Miller AB; Reid RA; Madauss KP; Hassell A; Hanlon MH; Porter DJ; Becherer JD; Carter LH
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4360-3. PubMed ID: 18606544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolyl oligopeptidase inhibition by N-acyl-pro-pyrrolidine-type molecules.
    Kánai K; Arányi P; Böcskei Z; Ferenczy G; Harmat V; Simon K; Bátori S; Náray-Szabo G; Hermecz I
    J Med Chem; 2008 Dec; 51(23):7514-22. PubMed ID: 19006380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors.
    Jarho EM; Venäläinen JI; Huuskonen J; Christiaans JA; Garcia-Horsman JA; Forsberg MM; Järvinen T; Gynther J; Männistö PT; Wallén EA
    J Med Chem; 2004 Nov; 47(23):5605-7. PubMed ID: 15509157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dicarboxylic acid bis(L-prolyl-pyrrolidine) amides as prolyl oligopeptidase inhibitors.
    Wallén EA; Christiaans JA; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J
    J Med Chem; 2002 Sep; 45(20):4581-4. PubMed ID: 12238937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPalpha).
    Gilmore BF; Lynas JF; Scott CJ; McGoohan C; Martin L; Walker B
    Biochem Biophys Res Commun; 2006 Jul; 346(2):436-46. PubMed ID: 16769036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dicarboxylic acid azacycle l-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme-inhibitor interactions.
    Jarho EM; Wallén EA; Christiaans JA; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J; Poso A
    J Med Chem; 2005 Jul; 48(15):4772-82. PubMed ID: 16033257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constrained peptidomimetics reveal detailed geometric requirements of covalent prolyl oligopeptidase inhibitors.
    Lawandi J; Toumieux S; Seyer V; Campbell P; Thielges S; Juillerat-Jeanneret L; Moitessier N
    J Med Chem; 2009 Nov; 52(21):6672-84. PubMed ID: 19888757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Slow-binding inhibitors of prolyl oligopeptidase with different functional groups at the P1 site.
    Venäläinen JI; Juvonen RO; Garcia-Horsman JA; Wallén EA; Christiaans JA; Jarho EM; Gynther J; Männistö PT
    Biochem J; 2004 Sep; 382(Pt 3):1003-8. PubMed ID: 15217351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and activity of pyrrolidinyl- and thiazolidinyl-dipeptide derivatives as inhibitors of the Tc80 prolyl oligopeptidase from Trypanosoma cruzi.
    Joyeau R; Maoulida C; Guillet C; Frappier F; Teixeira AR; Schrével J; Santana J; Grellier P
    Eur J Med Chem; 2000 Feb; 35(2):257-66. PubMed ID: 10758287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformationally rigid N-acyl-5-alkyl-L-prolyl-pyrrolidines as prolyl oligopeptidase inhibitors.
    Wallén EA; Christiaans JA; Saarinen TJ; Jarho EM; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J
    Bioorg Med Chem; 2003 Aug; 11(17):3611-9. PubMed ID: 12901906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benzimidazolium salts as small, nonpeptidic and BBB-permeable human prolyl oligopeptidase inhibitors.
    Tarragó T; Masdeu C; Gómez E; Isambert N; Lavilla R; Giralt E
    ChemMedChem; 2008 Oct; 3(10):1558-65. PubMed ID: 18792035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent, small-molecule inhibitors of human mast cell tryptase. Antiasthmatic action of a dipeptide-based transition-state analogue containing a benzothiazole ketone.
    Costanzo MJ; Yabut SC; Almond HR; Andrade-Gordon P; Corcoran TW; De Garavilla L; Kauffman JA; Abraham WM; Recacha R; Chattopadhyay D; Maryanoff BE
    J Med Chem; 2003 Aug; 46(18):3865-76. PubMed ID: 12930148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP.
    Tran T; Quan C; Edosada CY; Mayeda M; Wiesmann C; Sutherlin D; Wolf BB
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1438-42. PubMed ID: 17174090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The natural product berberine is a human prolyl oligopeptidase inhibitor.
    Tarrago T; Kichik N; Seguí J; Giralt E
    ChemMedChem; 2007 Mar; 2(3):354-9. PubMed ID: 17295371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolyl oligopeptidase and its role in the organism: attention to the most promising and clinically relevant inhibitors.
    Babkova K; Korabecny J; Soukup O; Nepovimova E; Jun D; Kuca K
    Future Med Chem; 2017 Jun; 9(10):1015-1038. PubMed ID: 28632451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of serine protease inhibitors with conformation restricted by amino acid side-chain-side-chain CH/pie interaction.
    Shimohigashi Y; Nose T; Yamauchi Y; Maeda I
    Biopolymers; 1999; 51(1):9-17. PubMed ID: 10380349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dynamics, crystallography and mutagenesis studies on the substrate gating mechanism of prolyl oligopeptidase.
    Kaszuba K; Róg T; Danne R; Canning P; Fülöp V; Juhász T; Szeltner Z; St Pierre JF; García-Horsman A; Männistö PT; Karttunen M; Hokkanen J; Bunker A
    Biochimie; 2012 Jun; 94(6):1398-411. PubMed ID: 22484394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular dynamics study of prolyl oligopeptidase with inhibitor in binding cavity.
    Kaszuba K; Rog T; St Pierre JF; Mannisto PT; Karttunen M; Bunker A
    SAR QSAR Environ Res; 2009 Oct; 20(7-8):595-609. PubMed ID: 20024801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and evaluation of peptide-based prolyl oligopeptidase inhibitors--introduction of N-benzyloxycarbonyl-prolyl-3-fluoropyrrolidine as a lead in inhibitor design.
    Goossens F; Vanhoof G; De Meester I; Augustyns K; Borloo M; Tourwe D; Haemers A; Scharpé S
    Eur J Biochem; 1997 Nov; 250(1):177-83. PubMed ID: 9432007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.